RxDoctor Payments Data

Pablo Bisono Rodriguez, MD

Internal Medicine · Rio Piedras, PRNPI 1366412801

Payments from drug & device makers

$3,043in general payments, 2019–2025

Across 39 payments — averaging $78.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$250
  • AstraZeneca$148
  • Boston Scientific$83
  • PBG Puerto Rico LLC$41
  • Pfizer$35
  • plus $70 from 3 others

What the payments were for

  • Consulting fees$1,60053%
  • Travel & lodging$191%
  • Food & beverage$1,36045%
  • Education$642%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson26$2,417
E.r. Squibb & Sons, L.L.C.4$250
AstraZeneca2$148
Boston Scientific1$83
PBG Puerto Rico LLC2$41
Pfizer1$35
Dexcom, Inc.1$25
Novartis1$24
Seqirus USA Inc1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,043 in reported general payments places this provider in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$12,376
Medicare patients
28
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban86$90,967
EliquisApixaban78$57,358
FarxigaDapagliflozin Propanediol50$47,230
JardianceEmpagliflozin26$34,671
JanuviaSitagliptin Phosphate27$30,771
EntrestoSacubitril/Valsartan28$29,720
SynthroidLevothyroxine Sodium242$29,368
MounjaroTirzepatide19$20,055
JanumetSitagliptin Phos/Metformin Hcl15$14,947
TradjentaLinagliptin14$10,475
LantusInsulin Glargine,hum.Rec.Anlog85$9,945
HumalogInsulin Lispro51$6,926
Breo ElliptaFluticasone/Vilanterol14$5,806
Rosuvastatin Calcium296$5,440
Atorvastatin Calcium415$5,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$2,417$90,96786 claims
PfizerEliquis$35$57,35878 claims
AstraZenecaFarxiga$148$47,23050 claims
NovartisEntresto$24$29,72028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Rio Piedras

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →